Payment overview · 2025
General Payments
$715.69
35 reported records · 8 companies
Healthcare provider profile · identity verified
Dae Soon Rheem, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1295915585
Verified facts
What the public records show
CMS Open Payments records show Dae Soon Rheem, M.D. received $715.69 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 518 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 401 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Viberzi by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 350 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $173.06 | 24.2% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $160.39 | 22.4% | 13 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.16 | 14.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $95.75 | 13.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.02 | 9.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.68 | 7.6% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $33.48 | 4.7% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $31.15 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $715.69 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $160.39 | 13 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $102.16 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $97.13 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $84.03 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $70.36 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.68 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.45 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $33.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.44 | 1 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $33.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.58 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 518 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 401 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 350 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 189 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
518 | 134 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
401 | 111 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
31 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
189 | 54 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
350 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 4370 | 1194 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 3684 | 834 |
| Ezetimibe | Ezetimibe | 1967 | 435 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1850 | 508 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 1636 | 334 |
| Ursodiol | Ursodiol | 1279 | 278 |
| Losartan Potassium | Losartan Potassium | 1200 | 271 |
| Glipizide Er | Glipizide | 1194 | 184 |
| Jardiance | Empagliflozin | 1136 | 166 |
| Finasteride | Finasteride | 1020 | 207 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 880 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 817 | 140 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 796 | 369 |
| Pioglitazone Hcl | Pioglitazone Hcl | 727 | 145 |
| Tamsulosin Hcl | Tamsulosin Hcl | 541 | 119 |
| Repatha Sureclick | Evolocumab | 534 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 527 | 117 |
| Creon | Lipase/Protease/Amylase | 518 | 134 |
| Metformin Hcl | Metformin Hcl | 408 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 69 |
| Linzess | Linaclotide | 401 | 111 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 391 | 379 |
| Metformin Hcl Er | Metformin Hcl | 352 | 84 |
| Ozempic | Semaglutide | 350 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 66 |
| Lidocaine | Lidocaine | 327 | 66 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 279 | 115 |
| Farxiga | Dapagliflozin Propanediol | 276 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 268 | 64 |
| Praluent Pen | Alirocumab | 251 | 44 |
| Tramadol Hcl | Tramadol Hcl | 238 | 107 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 226 | 60 |
| Mesalamine | Mesalamine | 211 | 56 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 209 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 190 | 86 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 189 | 54 |
| Pregabalin | Pregabalin | 185 | 37 |
| Memantine Hcl Er | Memantine Hcl | 179 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 165 | 44 |
| Dexlansoprazole Dr | Dexlansoprazole | 162 | 40 |
| Alprazolam | Alprazolam | 159 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 38 |
| Montelukast Sodium | Montelukast Sodium | 152 | 24 |
| Zenpep | Lipase/Protease/Amylase | 150 | 45 |
| Memantine Hcl | Memantine Hcl | 119 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 118 | 18 |
| Eliquis | Apixaban | 116 | 23 |
| Januvia | Sitagliptin Phosphate | 116 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 114 | 20 |
| Trazodone Hcl | Trazodone Hcl | 111 | 31 |
| Furosemide | Furosemide | 109 | 29 |
| Ketoconazole | Ketoconazole | 109 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 18 |
| Gabapentin | Gabapentin | 105 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 104 | 20 |
| Minoxidil | Minoxidil | 104 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 103 | 37 |
| Allopurinol | Allopurinol | 95 | 17 |
| Methotrexate | Methotrexate Sodium | 89 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | 12 |
| Valacyclovir | Valacyclovir Hcl | 87 | 49 |
| Tadalafil | Tadalafil | 86 | 17 |
| Azathioprine | Azathioprine | 85 | 16 |
| Sutab | Sod Sulf/Pot Chloride/Mag Sulf | 84 | 83 |
| Carvedilol | Carvedilol | 81 | 16 |
| Donepezil Hcl | Donepezil Hcl | 81 | 17 |
| Celecoxib | Celecoxib | 79 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 24 |
| Entacapone | Entacapone | 76 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 24 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 72 | 12 |
| Levofloxacin | Levofloxacin | 71 | 43 |
| Unifine Pentips | Pen Needle, Diabetic | 71 | 17 |
| Brilinta | Ticagrelor | 70 | suppressed |
| Baclofen | Baclofen | 69 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 15 |
| Procto-Med Hc | Hydrocortisone | 68 | 23 |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 67 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | suppressed |
| Temazepam | Temazepam | 62 | 19 |
| Meclizine Hcl | Meclizine Hcl | 61 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 19 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 54 | 18 |
| Repatha Pushtronex | Evolocumab | 54 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 52 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | suppressed |
| Vascepa | Icosapent Ethyl | 48 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Prednisone | Prednisone | 44 | 21 |
| Lansoprazole | Lansoprazole | 41 | 15 |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 40 | suppressed |
| Plenvu | Peg3350/Sod Sul/Nacl/Kcl/Asb/C | 40 | 40 |
| Tradjenta | Linagliptin | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 11 |
| Entecavir | Entecavir | 38 | suppressed |
| Loperamide | Loperamide Hcl | 38 | 25 |
| Nitroglycerin | Nitroglycerin | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 32 | 16 |
| Dexilant | Dexlansoprazole | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 21 |
| Suprep | Sodium, Potassium,mag Sulfates | 31 | 31 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Fluocinonide | Fluocinonide | 30 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 29 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | 12 |
| Nystatin | Nystatin | 28 | 21 |
| Amoxicillin | Amoxicillin | 26 | 24 |
| Clotrimazole | Clotrimazole | 26 | 12 |
| Folic Acid | Folic Acid | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 12 |
| Atenolol | Atenolol | 19 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 17 | suppressed |
| Budesonide Ec | Budesonide | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Viberzi | Eluxadoline | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 13 | 13 |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Glipizide Xl | Glipizide | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $715.69 · 35 records | ABBVIE INC. | CREON, EVENITY, IBSRELA, Kerendia, LINZESS, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, SIMPONI, SIMPONI ARIA, STELARA, TRELEGY ELLIPTA, TREMFYA, Tresiba, UBRELVY, VOQUEZNA, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error